{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T10:37:02Z","timestamp":1785580622382,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019210","name":"University Health Network Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.semarthrit.2025.152859","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:11:31Z","timestamp":1761617491000},"page":"152859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Incidence and predictors of primary failure of targeted therapy in patients with Psoriatic Arthritis"],"prefix":"10.1016","volume":"75","author":[{"given":"Fadi","family":"Kharouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"AlHadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2025.152859_bib0001","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2025.152859_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152859_bib0003","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1191\/096120399680411443","article-title":"Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients","volume":"8","author":"FitzGerald","year":"1999","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152859_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152859_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.berh.2018.12.002","article-title":"An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis","volume":"32","author":"So","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152859_bib0006","first-page":"1","article-title":"Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies","author":"Kharouf","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2025.152859_bib0007","doi-asserted-by":"crossref","DOI":"10.2174\/0115733971339350240830104424","article-title":"Updates on recent advances in the therapy of adult psoriatic disease","author":"Kharouf","year":"2025","journal-title":"Curr Rheumatol Rev"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152859_bib0008","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.3390\/ijms24076384","article-title":"Targeted therapies in psoriatic arthritis-an update","volume":"24","author":"Sundanum","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152859_bib0009","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/acr.25112","article-title":"Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort","volume":"75","author":"Rida","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152859_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152859_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152859_bib0012","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","article-title":"Primary and secondary non-response: in need of operational definitions in observational studies","volume":"80","author":"Vallejo-Yag\u00fce","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152859_bib0013","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an anti-TNF agent in inflammatory bowel disease: switch (to a Second Anti-TNF Agent) or swap (for Another Mechanism of Action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"JCM"},{"issue":"1415","key":"10.1016\/j.semarthrit.2025.152859_bib0014","first-page":"34","article-title":"Retention on anti-tumour necrosis factor therapy: the Waikato experience","volume":"128","author":"Ip","year":"2015","journal-title":"N Z Med J"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152859_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"Di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152859_bib0016","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/rheumatology\/keq091","article-title":"Time and predictors of response to tumour necrosis factor- blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort","volume":"49","author":"Eder","year":"2010","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152859_bib0017","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152859_bib0018","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152859_bib0019","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology (Oxford)."},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152859_bib0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/1744666X.2014.905741","article-title":"Predictors for clinical outcome in psoriatic arthritis \u2013 what have we learned from cohort studies?","volume":"10","author":"Eder","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152859_bib0021","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152859_bib0022","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","article-title":"Radiological assessment in psoriatic arthritis","volume":"37","author":"Rahman","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152859_bib0023","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis","volume":"27","author":"Linden","year":"1984","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152859_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/keq262","article-title":"Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program","volume":"50","author":"Gladman","year":"2011","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0026","first-page":"886","article-title":"Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification","volume":"22","author":"Blackmore","year":"1995","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0027","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/bjd.20577","article-title":"Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study*","volume":"185","author":"Iskandar","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2025.152859_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/acr.25513","article-title":"Association between metabolic syndrome and radiographic changes in psoriatic arthritis: a cohort study","author":"Kharouf","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0029","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152859_bib0030","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor \u03b1 blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152859_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152859_bib0032","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.1780311102","article-title":"Formal education level as a significant marker of clinical status in rheumatoid arthritis","volume":"31","author":"Callahan","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0033","first-page":"1045","article-title":"Remission in psoriatic arthritis","volume":"28","author":"Gladman","year":"2001","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152859_bib0034","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152859_bib0035","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3021","article-title":"Remission in psoriatic arthritis: is it possible and how can it be predicted?","volume":"12","author":"Saber","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152859_bib0036","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.2023-0716","article-title":"Residual disease activity in Canadian patients with psoriatic arthritis treated with advanced therapies: results from a multiregistry analysis (UNISON-PsA)","volume":"51","author":"Gladman","year":"2024","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152859_bib0037","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model","volume":"22","author":"Gladman","year":"1995","journal-title":"J Rheumatol"},{"issue":"01","key":"10.1016\/j.semarthrit.2025.152859_bib0038","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152859_bib0039","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","article-title":"Minimal disease activity and anti\u2013Tumor necrosis factor therapy in psoriatic arthritis","volume":"67","author":"Haddad","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2025.152859_bib0040","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review","volume":"12","author":"Murage","year":"2018","journal-title":"Patient Prefer Adherence"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:39:02Z","timestamp":1773905942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["S0049017225002306"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152859","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and predictors of primary failure of targeted therapy in patients with Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152859"}}